Protheragen to Bridge Innovation at BIOCHINA 2026

Online Inquiry

---

Protheragen, a premier US-based group specializing in pharmaceutical investment, incubation, and global business development (BD), is proud to announce its participation in BIOCHINA 2026 (www.biocn.cn). Headquartered in New York, Protheragen is dedicated to the cross-border movement of breakthrough biomedical assets.

A Professional BD Powerhouse with Global Resources

Protheragen is a strategic partner for companies navigating the complexities of the global biopharma landscape. With deep roots in the US and a vast innovation network, we provide comprehensive BD services designed to unlock value for every stakeholder in the ecosystem.

• For Biotechs & Startups: Your Launchpad to the World

We empower innovative companies with “Go-Global” ambitions. Whether you are seeking international out-licensing opportunities, cross-border financing, or global co-development, Protheragen leverages its US-based expertise and extensive industry connections to elevate your project from a local success to a global contender.

• For Pharma & Investors: A Curated Portfolio of High-Potential Assets

For pharmaceutical companies looking to fortify their pipelines or investment institutions seeking the next “blockbuster,” Protheragen serves as a professional asset sourcing hub. We offer a diverse range of high-potential assets:

• Full Spectrum Maturity: From early-stage discovery to late-stage clinical trials.
• Cutting-Edge Modalities: Innovative Small Molecules, Antibodies (mAb, BsAb, TsAb), ADCs, Cell & Gene Therapies, etc.etc

The “Dual-BIO” Strategic Bridge

Our presence at BIOCHINA 2026 in Suzhou serves as a critical domestic starting point for our “Progressive Cooperation Path.” We understand that internationalization is a journey, not a single event.

By engaging with us in Suzhou, partners gain a direct link to the BIO International Convention 2026 in San Diego this June. Protheragen will ensure that high-quality projects identified at BIOCHINA receive sustained, deep-dive promotion on the world’s largest biotech stage in California, facilitating seamless transitions into the global market.

Meet Us in Suzhou

We cordially invite Biopharmaceutical companies seeking global licensing, Pharmaceutical corporations looking for pipeline additions, and Investment firms scouting for high-value assets to connect.

Join us to explore how Protheragen’s professional BD services and resource-rich network can accelerate your strategic goals. Let’s shape the future of global healthcare together.

• Event: BIOCHINA 2026
• Location: Suzhou International Expo Centre
• Date: 3/12 – 3/14
• Book a Meeting: We invite you to schedule a meeting through the official conference scheduling system, or contact us via email.

About Protheragen

Our core services aim to precisely connect innovative pharmaceutical assets with potential partners worldwide.

• Core Identity: A Global Strategic Bridge

• Dual-Hub Presence: Headquartered in New York with on-the-ground teams in both the US and China.
• Multidisciplinary Team: Integrates PhD-level scientific insight, global business development (BD) execution, and cross-border legal/transactional risk management.
• Proven Track Record: Over 10 years of expertise in cross-border transactions, managing 200+ partner relationships and a vault of 500+ real assets.

• Dual Value Proposition

• Protheragen leverages “information and professional gaps” to create efficiency for both sides of a deal:
• For Asset Owners (Sellers): Acts as the “hands, eyes, and voice” in the Western market. We bridge the gap for those lacking US-based BD capabilities, localized promotion resources, or international negotiation experience.
• For Potential Partners (Buyers): Provides zero-cost access to high-quality, pre-vetted assets. We act as an extended BD arm, helping buyers efficiently discover premium assets that are otherwise difficult to access.